CRMD - Rasio utang marang kapitalisasi buku CorMedix Inc

CorMedix Inc. (CRMD) is protected by unique patents for catheter antiseptics, which blocks competitors under strict FDA oversight. This chart reflects a current share price of 0.30, while the company is betting on organic growth and the search for distribution partners. The business remains independent of economic cycles, relying instead on certification cycles for dialysis infection prevention tools.

CRMD (CorMedix Therapeutics) riwayat Utang marang nilai buku saka 04.07.2022 nganti 29.10.2026

Rincian metrik lan analitis perusahaan CorMedix Inc (CRMD)

- rega lan prakiraan konsensus rega:

Rega saham CorMedix Inc.|CRMD - Prakiraan konsensus analis

- data kapitalisasi pasar:

Nilai pasar CorMedix Therapeutics|CRMD - Nilai Dipunlarasaken Utang lan Kas

- data kapitalisasi buku:

Aset Bersih saben Siji Saham CorMedix|CRMD - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku cormedix.com|CRMD - Total Aset Perusahaan

- data utang lan likuiditas:

Rasio Total Utang marang Ekuitas CorMedix Inc.|CRMD - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal CorMedix Corp|CRMD - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku CorMedix Therapeutics|CRMD - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan CorMedix

Ringkesan analitik perusahaan:CRMD - CorMedix Inc.

Investors are assessing the potential of CorMedix Inc. (CRMD) through the lens of debt load, where the debt-to-equity ratio determines the business's financial stability. By analyzing the current debt-to-equity ratio, one can understand how effectively strategic alliances with dialysis centers are funded through leverage, which characterizes the company as a high-risk asset with significant leverage.

Pesaing CorMedix Inc.